Healthcare / BiotechnologyBrussels
$0.29
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-6.9M · quality 48.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
25/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$13M
P/E
14.5x
↓EV/EBITDA
10.9x
↓ROE
34.1%
↑Gross Margin
61.9%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-32857.1%
FCF / Net income
-8.31x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $21000.0 · net income $830000.0 · FCF $-6.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $21000.00 | $21000.00 | $186000.00 | $102000.00 | — |
| Net Income | $830000.00 | $830000.00 | $-5.8M | $-8.4M | $-40.9M |
| EBITDA | $1.1M | $1.1M | $-5.3M | $-7.6M | $-39.2M |
| EPS | 0.02 | 0.02 | -0.14 | -0.34 | -1.81 |
| Gross Margin | 61.9% | 61.9% | 93.0% | 32.4% | — |
| Operating Margin | -6400.0% | -6400.0% | -3154.3% | -9238.2% | — |
| Net Margin | 3952.4% | 3952.4% | -3131.2% | -8282.4% | — |
| Balance Sheet | |||||
| Debt/Equity | — | — | 1.77 | 0.17 | 0.06 |
| Current Ratio | 1.92 | 1.92 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-6.9M | $-6.9M | $-5.8M | $-16.1M | $-28.1M |
| Returns | |||||
| ROE | 34.1% | 34.1% | -1137.5% | -134.0% | -948.2% |
| Valuation | |||||
| P/E | 14.50 | 14.50 | — | — | — |
| EV/EBITDA | 10.94 | 10.94 | — | — | — |
| P/B | 5.49 | 5.49 | 55.18 | 1.55 | 3.20 |
| Growth & Yield | |||||
| Revenue Growth | -88.7% | -88.7% | 82.4% | — | — |
| EPS Growth | 112.9% | 112.9% | 58.8% | 81.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
12.7%
EPS terminal req.
$0.03
Spread vs growth
100.2%
5Y implied EPS CAGR
11.6%
EPS terminal req.
$0.03
Spread vs growth
101.3%
10Y implied EPS CAGR
10.8%
EPS terminal req.
$0.05
Spread vs growth
102.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-33.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.14 → 0.02
Residual
-33.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.